Table 1.
Immunomodulatory drugs investigated in the treatment of COVID-19.
| Class (Mechanisms of action) | Drugs |
|---|---|
| IL-6 inhibitors | Tocilizumab |
| Sarilumab | |
| IL-1 antagonists | Anakinra |
| Canakinumab* | |
| Bruton`s Tirosin Kinase (BTK) inhibitors | Acalabrutinib* |
| Janus Kinase (JAK) inhibitors | Baricitinib |
| Tofacitinib | |
| Ruxolitinib* | |
| TNF inhibitors | Adalimumab* |
| Certolizumab* | |
| Infliximab* | |
| Etanercept* | |
| Golimumab* | |
| Anti CD6monoclonal antibodies | Itolizumab* |
| C5 complement inhibitors | Ravulizumab* |
| GM-CSF inhibitors | Lemilumab* |
*
There is not enough data to consider its use.